Phosphoramidon, a metalloproteinase inhibitor, suppresses the hypertensive effect of big endothelin-1

Eur J Pharmacol. 1990 Aug 21;185(1):103-6. doi: 10.1016/0014-2999(90)90216-s.

Abstract

Intravenous (i.v.) injection of big endothelin-1 (1-39, 0.05-1.0 nmol/kg) to anaesthetized rats produced a dose-dependent and long-lasting hypertensive effect, the magnitude of which was similar to that evoked by ET-1 (1-21). In animals given phosphoramidon (0.25 mg/kg per min i.v.), a metalloproteinase inhibitor, the hypertensive effect of big endothelin-1 was markedly attenuated. The same dose of phosphoramidon did not influence the endothelin-1-induced hypertensive effect. The possibility that big endothelin-1 is converted to endothelin-1 by a phosphoramidon-sensitive metalloproteinase in vivo warrants further attention.

MeSH terms

  • Anesthesia
  • Animals
  • Blood Pressure / drug effects*
  • Dose-Response Relationship, Drug
  • Endothelin-1
  • Endothelins / antagonists & inhibitors*
  • Endothelins / pharmacology
  • Glycopeptides / pharmacology*
  • Injections, Intravenous
  • Male
  • Metalloendopeptidases / antagonists & inhibitors*
  • Protein Precursors / antagonists & inhibitors*
  • Protein Precursors / pharmacology
  • Rats
  • Rats, Inbred Strains

Substances

  • Endothelin-1
  • Endothelins
  • Glycopeptides
  • Protein Precursors
  • Metalloendopeptidases
  • phosphoramidon